Abstract The blood-brain barrier (BBB) is compromised in brain metastases, allowing for enhanced drug permeation into brain. The extent and heterogeneity of BBB permeability in metastatic lesions is important when considering the administration of chemotherapeutics. Since permeability characteristics have been described in limited experimental models of brain metastases, we sought to define these changes in five brain-tropic breast cancer cell lines: MDA-MB-231BR (triple negative), MDA-MB-231BR-HER2, JIMT-1-BR3, 4T1-BR5 (murine), and SUM190 (inflammatory HER2 expressing). Permeability was assessed using quantitative autoradiography and fluorescence microscopy by co-administration of the tracers 14 C-aminoisobutyric acid (AIB) and Texas red conjugated dextran prior to euthanasia. Each experimental brain metastases model produced variably increased permeability to both tracers; additionally, the magnitude of heterogeneity was different among each model with the highest ranges observed in the SUM190 (up to 45-fold increase in AIB) and MDA-MB-231BR-HER2 (up to 33-fold in AIB) models while the lowest range was observed in the JIMT-1-BR3 (up to 5.5-fold in AIB) model. There was no strong correlation observed between lesion size and permeability in any of these preclinical models of brain metastases. Interestingly, the experimental models resulting in smaller mean metastases size resulted in shorter median survival while models producing larger lesions had longer median survival. These findings strengthen the evidence of heterogeneity in brain metastases of breast cancer by utilizing five unique experimental models and simultaneously emphasize the challenges of chemotherapeutic approaches to treat brain metastases. 
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Introduction
Effective drug delivery to brain metastases relies on a chemotherapeutic's ability to penetrate the blood-brain barrier (BBB) and/or blood-tumor barrier (BTB) such that adequate concentrations of therapeutics accumulate within lesions [1] . Despite the constant development of promising new drugs to treat primary breast cancer [2] , fewer than 2 % of new central nervous system (CNS) drug candidates receive approval for clinical use because of suboptimal BBB penetration [3] . The BBB employs both morphologic and physiologic characteristics that distinguish brain vasculature from peripheral vasculature [4] . The presence of these physical, enzymatic, and transport barriers of the BBB collectively serves a protective and regulatory role by preventing potentially deleterious compounds and substances from gaining access to the CNS [5, 6] .
The capillary endothelial cells that contribute to the BBB are structurally reinforced by a dense network of tight junction proteins that restrict drug distribution into brain by forming a physical barrier that limits drug diffusion from blood to brain [7, 8] . These tight junction proteins anchor capillary endothelial cells together such that the transendothelial electrical resistance (TEER) across brain capillary endothelial cells is significantly greater than peripheral vascular endothelial cells [9, 10] . Essentially, tight junction proteins at the BBB reinforce the intercellular interface between capillary endothelial cells similar to a continuous cell membrane. Further, the close association of pericytes and astrocyte foot processes surrounding the vascular endothelial cells of the BBB provide additional physical barriers, which limit passive diffusion of polar and large drugs into brain [11] [12] [13] . In addition to the physical barriers presented by the vascular endothelium, pericytes, and astrocyte foot processes, these cells express a number of drug metabolizing enzymes that inactivate drugs that can further reduce the distribution of active drugs to brain [14, 15] . Overall, the passive diffusion of most drugs, particularly those having a large molecular weight, are charged, and hydrophilic show limited permeation into brain compared to drugs that are small, uncharged, and lipophilic [16] [17] [18] .
The growth of metastases within the brain has been shown to variably contribute to increased permeability of the adjacent neurovasculature [19, 20] . Cells supporting the neurovasculature, such as pericytes and astrocytes, lose intimate association with capillary endothelial cells during the proliferation of intracranial metastases, which compromise the integrity of the BBB resulting in increased permeability [21] [22] [23] . Brain microvessels associated with proliferating metastases develop fenestrations [24] , increase pinocytic vesicles [25] , and exhibit decreased and displaced tight junction proteins [26, 27] . The permeability of the microvasculature of brain tumors and metastatic lesions (blood-tumor barrier, BTB) has been reported to range from one to two orders of magnitude greater than normal brain vasculature [28, 29] . The increases in BTB permeability makes magnetic resonance imaging (MRI) of metastatic lesions possible by enhancing gadolinium permeation across tumor microvessels [30] . Importantly, drug distribution and, to a certain degree, efficacy of chemotherapy has been shown to correlate with BTB permeability [31, 32] . Therefore, the evaluation of vascular permeability in experimental brain metastases models will provide insight into clinical responses to chemotherapy and may help to inform the design of novel chemotherapeutics that must penetrate the BTB to achieve efficacy.
Herein, we have characterized BTB permeability using two passive permeability markers, 14 C-AIB (104 Da) and Texas red dextran (TRD) (3 kDa), in five experimental models of brain metastases of breast cancer in mice. These brain-tropic cell lines include the MDA-MB 231BR and the MDA-MB-231BR-HER2? line (a HER-2 transfectant of the MDA-MB-231BR [33] ). We also evaluate a recently reported naturally overexpressing HER2? cell line (JIMT-1-BR3) [34] , the 4T1-BR5 [35] , a brain seeking line derived from the murine 4T1 mammary carcinoma cell line, and lastly the estrogen receptor negative/HER2? SUM190 inflammatory breast cancer cell line that is also brain specific (denoted as SUM190-BR3). We observed that all metastases from each cell line demonstrated a significant increase in permeability compared to normal brain with both passive markers. Passive permeability increases were highest in the SUM190-BR3 (for 14 C-AIB) and 4T1-BR5 (for TRD) model and lowest in the JIMT-1-BR3 (for 14 C-AIB) and MDA-MB-231BR (for TRD) model. Further, permeability changes varied both within and in between metastases without an apparent pathological correlation to size, density or invasiveness. Lastly, relevant to the model used predominantly in this experiment, we observed that changes in BTB permeability in the MDA-MB-231BR cell line significantly increased during the period of 21-28 days of development and stayed relatively stable until death.
Materials and methods

Chemicals and reagents
Texas red conjugated dextran (3 kDa) (TRD) was purchased from Molecular Probes-Life Technologies (Carlsbad, CA).
14 C-labelled aminoisobutyric acid (AIB) was purchased from American Radiolabelled Chemicals (St. Louis, MO). Cresyl violet acetate (0.1 %) was purchased from SigmaAldrich (St. Louis, MO). Firefly D-luciferase potassium salt was purchased from Caliper-PerkinElmer (Waltham, MA). All chemicals and reagents used were of analytical grade and were used as supplied.
Cell culture
Human MDA-MB-231BR, JIMT-1-BR3, and murine 4T1-BR5 mammary carcinoma cells were grown in DMEM supplemented with 10 % FBS. Human MDA-MB-231-HER2? metastatic breast cancer cells over-expressing HER2 (also expressing enhanced green fluorescent protein, eGFP) were cultured in DMEM supplemented with 10 % FBS and zeocin (300 lg/ml). SUM190-BR3 cells were grown in Ham-F12 media supplemented with 1 lg/ml hydrocortisone, 10 mM HEPES, 5 lg/ml insulin, 50 nm sodium selenite, 5 lg/ml transferrin, 10 nm tri-iodothyronine (T3), and 1 g/L bovine serum albumin (BSA). All cells were used in passages 1-10 and maintained at 37°C with 5 % CO2. For all cell preparations for intracardiac injection, cells were harvested at 70 % confluency. All cell lines were kindly provided by the laboratory of Dr. Patricia Steeg at the National Cancer Institute.
Experimental brain metastases model
Experiments were conducted under approved institutional Animal Care and Use Committee protocols (TTUHSC #06024 and WVU #13-1207) and all work followed internationally recognized animal welfare guidelines. Female athymic nu/nu mice (24-30 g) were purchased from Charles River Laboratories (Wilmington, MA) and were used as the experimental metastases platform in this study. All animals were 6-8 weeks of age at the initiation of the metastases models and were housed in a barrier facility. Mice were anesthetized under 2 % isoflurane and inoculated with 175,000 breast cancer cells (for each model) in the left cardiac ventricle with the aid of a stereotaxic device (Stoelting, Wood Dale, IL). Injection accuracy was evaluated by a pulsatory flow of bright red blood into the syringe upon slight retraction of the plunger prior to injection. After intracardiac injection, mice were placed in a warmed (37°C) sterile cage and vitals monitored until fully recovered. Metastases were allowed to develop until neurologic symptoms appeared (12-70 days) and animals were anesthetized with ketamine/xylazine (100 and 8 mg/kg respectively) prior to TRD (6 mg/kg) and 14 C-AIB (10 or 25 lCi) injection via IV bolus dose (femoral vein). The TRD and 14 C-AIB were allowed to circulate for 10 min prior to euthanasia. Immediately, the brain was rapidly removed (less than 60 s) and flash-frozen in isopentane (-65°C) and stored at -20°C.
Tissue processing and analysis
Brain slices (20 lm thick) were acquired with a cryotome (Leica CM3050S; Leica Microsystems, Wetzlar, Germany) and transferred to charged microscope slides (three brain slices per microscope slide; each brain produces approximately 70-100 slides total). Fluorescence images of brain slices were acquired using a stereomicroscope (Olympus MVX10; Olympus, Center Valley, PA) equipped with a 0.5 NA 29 objective and a monochromatic cooled CCD scientific camera (Retiga 4000R, QIMaging, Surrey, BC, Canada). Texas red fluorescence was imaged using a DsRed sputter filter (excitation/band k 545/25 nm, emission/band k 605/70 nm and dichromatic mirror at k 565 nm) (Chroma Technologies, Bellows Falls, VT) and enhanced green fluorescent protein (expressed in MDA-MB-231BR-HER2?) using an ET-GFP sputter filter (excitation/band k 470/40 nm, emission/band k 525/50 nm and dichromatic mirror at k 495 nm) (Chroma Technologies, Bellows Falls, VT). Fluorescence image capture and analysis software (SlideBook 5.0; Intelligent Imaging Innovations Inc., Denver, CO) was used to capture and quantitate fluorescence images. Texas red permeability fold-changes were determined by Texas red sum intensity (SI) per unit area of metastases relative to the SI per area of contralateral normal brain regions. If metastases occurred in contralateral regions, adjacent slices containing unaffected tissues of the same brain structure were used as comparative normal brain regions.
Quantitative autoradiography (QAR)
After fluorescence imaging of tissue, slides were placed in QAR cassettes (FujiFilm Life Sciences, Stamford, CT) along with 14 C autoradiographic standards (GE Healthcare, Piscataway, NJ). A phosphor screen (FujiFilm Life Sciences, 20 9 40 super-resolution) was placed with the slides and standards and allowed to develop for 6 up to 14 days. QAR phosphor screens were developed in a highresolution phosphor-imager (FUJI FLA-7000, FujiFilm Life Sciences) and converted to digital images. Digital QAR images were calibrated to 14 C standards and analyzed using MCID Analysis software (InterFocus Imaging LTD, Linton, Cambridge, England). Metastases permeability fold-changes were calculated based on 14 C-AIB signal intensity within confirmed metastases locations (determined by cresyl violet or eGFP fluorescence image overlays) relative to contralateral normal brain 14 C-AIB signal intensity.
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Cresyl violet staining
Tissue sections were processed as described above and subsequently fixed using 4 % paraformaldehyde followed by a rinse in PBS for 10 min. Staining was performed using 0. 
Results
In our first set of experiments we characterized BTB permeability ( Fig. 1 ) of 4T1 metastases (n = 229), which developed approximately 14 days after inoculating cells into the left cardiac ventricle. We characterized the 4T1 cell line since it is a highly metastatic cell line and can colonize in the lungs, liver, bone, and brain [35] . This model is often used to study the role of the immune system in tumor growth and metastasis since it is syngeneic in BALB/c mice [36] . We observed that when the animals developed neurological symptoms, passive permeability changes in the metastatic lesion ranged from 0.7 to 13-fold over normal brain with a median IQR fold change of 3.02 (2.2-4.5) for 14 C-AIB (Fig. 1a) . For the passive diffusion marker TRD, permeability ranged from 0.9 to 7.6-fold with a median IQR fold change of 2.53 (2.0-3.1) (Fig. 1b) . There was a poor correlation (r 2 = 0.23) to changes in 14 C-AIB passive permeability and size of the lesion (Fig. 1a) . No correlation was observed (r 2 = 0.07) for TRD passive permeability and metastasis size (Fig. 1b) .
The next model we evaluated was a brain-tropic derivative of the epithelial human carcinoma cell line JIMT-1 [34] . The primary cell line was established from a pleural metastasis of a 62 year-old breast cancer patient. [34] . Passive permeability changes in the JIMT-1-BR3 metastatic lesions (n = 256) at the time when brain metastases began to produce neurological symptoms were less than that of the 4T1 model, ranging from 1.1 to 6-fold over normal brain with a median (IQR) fold change of 2.08 (1.8-2.5) for 14 C-AIB (Fig. 2a) . Passive permeability of TRD fold changes ranged from 0.8 to 2.7-fold with a median IQR of 1.43 (1.3-1.6) (Fig. 2b) . As seen with the previous model, no correlation (r 2 = 0.004 for 14 C-AIB and r 2 = 0.007 for TRD) (Fig. 2a, b) between passive permeability and lesion size was observed.
Given that the JIMT-1 line is a naturally overexpressing HER2 cell line, we also chose to evaluate the brain-tropic MDA-MB-231BR-HER2? cell line transfected to overexpress HER2. The parent MDA-MB-231 cell line is a triple negative human cell line (estrogen, progesterone and HER2 receptor negative) that was derived from a metastatic adenocarcinoma of the mammary gland of a 51 yearold Caucasian woman and is epithelial in nature but poorly differentiated [37] . The parent line is highly aggressive and invasive, which has been useful in experimental metastases models studying various tissues [38] . Unlike the JIMT-1-BR3, line the MDA-MB-231BR-HER2? model produced metastatic lesions (n = 137) with higher permeability relative to normal brain for both 14 C-AIB and TRD (Fig. 3 ). Passive permeability fold changes ranged from 0.95 to 34-fold with a median IQR of 5.51 (3.1-8.8) for 14 C-AIB (Fig. 3a) while TRD permeability fold changes (Fig. 3b) ranged from 0.91 to 8.4-fold with a median IQR of 1.18 (1.1-1.6). However, similar to the previous models, we observed no correlation between passive permeability and tumor size (r 2 = 0.03 for 14 C-AIB and r 2 = 0.06 for TRD) (Fig. 3a, b) in the MDA-MB-231BR-HER2 model.
Since we did not see an initial correlation between HER2 and increases in lesion permeability, we then evaluated permeability in the brain seeking MDA-MB-231BR cell line model (without the HER2 transfectant). In this model we observed lesion (n = 235) permeability changes (Fig. 4a, b) when the animals developed neurological symptoms that were greater than the 4T1 and JIMT1 cell line model, but less than the MDA-MB-231BR-HER2? transfected model. Specifically, MDA-MB-231BR permeability changes with 14 C-AIB (Fig. 4a ) ranged 0.79 to 19-fold above normal brain with a median IQR of 2.31 (1.6-3.6). The BTB permeability to TRD (Fig. 4b) ranged (Fig. 4a, b) . The SUM190 cell line is a poorly differentiated inflammatory breast carcinoma. It does not express progesterone or estrogen receptors, but does express HER2 receptors [39] . Of note, inflammatory breast cancer tumors grow quickly and invade rapidly, and are typically highly vascular due to increased VEGF secretion [40] , so we hypothesized permeability could be compromised in brain metastases. The experimental SUM190-BR3 model produced metastatic lesions with the greatest permeability, and variability, relative to normal brain for 14 C-AIB (Fig. 5a) ; permeability fold changes ranged from 0.99 to 49-fold and had a median IQR of 11.9 (7.7-16.3). Although the 14 C-AIB in this model was greater relative to the other models tested, TRD permeability (Fig. 5b) remained modest exhibiting only a 0.74 to 3.5-fold increase and a median (IQR) of 1.43 (1.2-1.7). Like each of the previous models, the correlation of 14 C-AIB permeability and metastasis size in the SUM190-BR3 cell line (n = 285 metastases) was poor (r 2 = 0.21; Fig. 5a ) and the TRD (n = 143 metastases analyzed) permeability showed no correlation (r 2 = 0.008; Fig. 5b ) to lesion size.
Following the evaluation of permeability in each model, we compared the size of metastatic lesions in brain once animals became moribund (Fig. 6a) . Finally, we assessed the median survival in each model of experimental brain metastases of breast cancer (Fig. 6b) . The shortest median survival occurred in the 4T1-BR5 syngeneic model (14 days) while the highest median survival was seen in the SUM190-BR3 model (92 days). Of interest, median survival corresponded with the rank order of metastasis size, i.e., the longer the animal survived the larger the lesions. . Overall, we analyzed passive permeability in 998 experimental brain metastases in five different models. Permeability fold change values and their correlation to metastasis size are summarized in Table 1 .
Discussion
Herein we have characterized five breast cancer cell lines in an experimental model of metastases, which preferentially seed the brain. We have demonstrated that there are differences in the magnitude of passive permeability changes between each experimental model of brain metastases. Not surprisingly, we observed differences in median survival and the size of metastatic lesions at the time animals became moribund. The increased permeability of the vasculature at the BTB is critically important for both diagnosis and treatment. Imaging contrast agents such as gadolinium gain access to the CNS through increased vascular permeability within CNS lesion and are, therefore, useful in the clinic to define tumor location, the amount of peri-tumoral edema, vascularity of the lesion, and potentially the tumor type [41] . Recently, surgical oncologists have utilized the enhanced uptake of contrast agents such as gadolinium into CNS lesions as a guide during tumor resection as well as a tool to estimate patient prognosis and response to therapy [42] . Of interest to our work, some CNS tumor types appear non-enhancing or low enhancing in MRI [43, 44] , which suggests that vascular permeability changes in some tumor types are less than pronounced than other tumor types. Further, metastatic lesions have varying degrees of enhancement depending on type of tumor and location [45] . Our permeability work (notably with the small marker AIB) agrees with clinical imaging data suggesting not all lesions demonstrate enhancement to contrast agents uniformly.
Consistent with previous work [31, 46] , we demonstrate that changes in passive permeability are independent of lesion size, and do not appear to be related to tumor morphology. Moreover, the observed BTB permeability at different locations within the brain did not appear to influence permeability in these models supporting previous MRI studies examining the distribution of gadolinium-enhancing metastases in similar preclinical models [19] . The brain distribution of metastatic foci in each model presented herein appear consistent with similar studies demonstrating more than 50 % of metastatic burden occurs in cortical regions, with relatively fewer lesions occurring in the central brain regions, and the least metastatic growth observed in the posterior and olfactory regions [47, 48] . Additionally, this work agrees with previous findings [46] suggesting the presence of HER2 does not seem to correlate strongly with changes in vascular permeability (permeability of JIMT-1-BR3, SUM190-BR3, and MDA-MB-231BR-HER2? lines were not congruent) and that permeability changes appear to be more cell line specific (i.e., MDA-BB-231BR and MDA-MB-231BR-HER2 ?). Interestingly, Murell et al. observed much smaller SUM190-BR3 brain metastases relative to MDA-MB-231BR-HER2? . In our hands, the SUM190-BR3 model produced the largest metastases relative to the other four models of 5 SUM190-BR3 cells compared to 1.75 9 10 5 cells used to initiate our model. Similarly, number of cells injected has been previously shown to affect the number of metastases in preclinical brain metastases models [47, 49] . Despite the observed differences in relative lesion sizes and the reported sizes of SUM190-BR3 by Murrell et al., we observed similar survival patterns as those reported by their group. Inflammatory breast cancer metastases exhibit similar variability of permeability when compared to noninflammatory breast cancer metastases, though tumor size and median survival in the SUM190-BR3 model was greater relative to other models characterized herein.
It has been demonstrated that changes in lesion passive permeability are highly correlated to the degree of drug uptake as well as drug effect [31] . Unfortunately, the magnitude of passive permeability changes observed in this work, as well as earlier work [31] , suggest that fewer than *10 % of metastatic lesions exhibit a BTB vasculature leaky enough to permit efficacious drug concentrations into metastatic lesions using conventional chemotherapeutics. While the rules that govern CNS drug penetration have been studied extensively, drugs predicted to demonstrate excellent CNS distribution do not always translate to therapeutic concentrations of drug accessing brain parenchyma and metastatic cells within the brain. Various chlorambucil analogs, for example, with logP values ranging between *4.0 and 8.0 did not exhibit increased brain distribution than chlorambucil (logP of *2.6) due to greater peripheral distribution [50] . Similarly, the lipid soluble chemotherapeutic lapatinib produced drug concentrations in brain metastases only 10-20 % of what was observed in peripheral tumors [32] . This continues to highlight the need to develop novel drug formulations that specifically take advantage of this variable increase in BTB permeability to elevate and extend drug exposure within intracranial metastases. The integration of PEGylation as polymeric anti-cancer formulations, for example, has been shown to extend the plasma half-life of active drug equivalents without increasing toxicity and facilitate distribution to brain tumors by taking advantage of enhanced permeability at the BTB [51] .
Still, we do not fully understand what causes the variability in permeability changes among lesions of the same cell line within the same brain. It has been suggested that increased permeability may be related to any combination of the following factors: breakdown of the astrocyte-vascular endothelial interaction and loss of vascular pericyte coverage [52] , increased eNOS synthesis secondary to VEGF secretion from cancer cells [53] , the presence of inflammatory cytokines such as TGFb [54] , the process of angiogenesis [55] , and the dysregulation of tight junction proteins in the BTB [56] . Changes in vascular permeability may actually be a representation of all factors at one given time in the local tumor microenvironment. It is entirely possible that lesions in the CNS are undergoing varying degrees of remodeling, growth, and angiogenesis. Accordingly, we might be observing a single static snapshot of the vascular permeability at the time of sacrifice rather than a longitudinal and dynamic observation. Future work should set out to determine if permeability varies longitudinally as lesions develop, which may help improve clinical outcomes of brain metastases of breast cancer. 
